Sign in
WithdrawnNo phase

Renal Sympathetic Denervation Combined With Aorticorenal Ganglion Ablation for Treatment of Hypertension

Key facts

Who runs it
The Second Affiliated Hospital of Chongqing Medical University
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Withdrawn
Started
Mar 2025
Ended
Jan 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Renal sympathetic denervation
  • Renal sympathetic denervation plus aorticorenal ganglion ablation
Record updated
14 May 2025
Why it stopped
The hospital ethics review for this study is currently underway, and participant recruitment will commence once the approval is granted.

Who can take part

Age
18 years to 70 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (14)Hide the full registry criteria

Who can take part

  • Male and non-pregnant female subjects
  • 18≤age≤70 years old
  • Primary hypertension
  • 24-hour ASBP ≥130mmHg after standard anti-hypertensive drug therapy
  • Arteries meet the criteria of catheter manipulation
  • Patient understands the purpose of this study, and is willing to participate and sign the informed consent
  • Patient is compliant and willing to complete clinical follow-up

Who cannot take part

  • Participated other clinical trials including both drug and medical device studies within 3 months enrollment
  • Patients previously or currently suffering from one of the following diseases: 1) Essential pulmonary arterial hypertension; 2) Type I diabetes; 3) Severe cardiac valvular stenosis; 4) History of myocardial infraction (MI), unstable angina, syncope or cerebrovascular accidents within half year; 5) History of primary aldosteronism, pheochromocytoma, aorta stenosis, hyperthyroidism or hyperparathyroidism; 6) Any disease conditions interfering the measurement of blood pressure (for instance, severe peripheral artery diseases, abdominal artery aneurysm, hemorrhagic disorders such as thrombocytopenia, hemophilia and severe anemia); 7) Plans to have surgery or cardiovascular interventions within following 6 months; 8) Alcohol abuse or unknown drug dependence history; 9) Neuroticisms such as depression or anxiety disorders; 10) Non-compliant patients unable to finish the research per physician's requests
  • Abdominal aorta and renal arteries are not eligibility for catheter manipulation: 1) Renal artery stenosis >50% or any renal artery aneurysms on either side 2) History of renal artery percutaneous transluminal angioplasty (PTA), including balloon angioplasty and stenting; 3) abdominal aortic dissection, ulceration, or stenosis
  • eGFR <45ml/min/1.73m2 (MDRD formula)
  • Hospitalized within one year due to hypertensive crisis
  • Female with pregnant or lactating, or having plans for pregnancy within 1 year
  • Patient with sleep apnea who needs chronic oxygen-breathing or mechanical ventilation support (for example, tracheostomy)

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The purpose of this prospective cohort proof-of-concept trial is to compare the efficacy and safety of renal sympathetic denervation (RSD) plus aorticorenal ganglion ablation versus RSD alone in the treatment of uncontrolled primary hypertension.

The 2 groups in the trial

  • RSD groupExisting treatment, for comparison

    High-frequency stimulation (HFS) guided radiofrequency ablation from accessible branches to the opening of the renal artery.

    Treatment: Renal sympathetic denervation

  • RSD+ARGA groupTreatment being tested

    High-frequency stimulation (HFS) guided radiofrequency ablation from accessible branches to the opening of the renal artery, as well as HFS-guided ARG ablation.

    Treatment: Renal sympathetic denervation plus aorticorenal ganglion ablation

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Efficacy and Safety Comparison of Renal Sympathetic Denervation Combined With Aorticorenal Ganglion Ablation vs. Renal Sympathetic Denervation Alone for the Treatment of Hypertension: A Multicenter, Prospective, Proof-of-concept Cohort Trials.
Record updated
14 May 2025